Australia - engelsk - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - simvastatin, quantity: 5 mg - tablet, film coated - excipient ingredients: ascorbic acid; hypromellose; pregelatinised maize starch; purified talc; magnesium stearate; hyprolose; iron oxide yellow; lactose monohydrate; microcrystalline cellulose; butylated hydroxyanisole; titanium dioxide; citric acid monohydrate - zocor is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zocor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zocor is indicated in patients at high risk of chd (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zocor is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - simvastatin, quantity: 80 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; hypromellose; butylated hydroxyanisole; lactose monohydrate; microcrystalline cellulose; citric acid monohydrate; purified talc; ascorbic acid; pregelatinised maize starch; titanium dioxide; iron oxide red - zocor is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zocor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zocor is indicated in patients at high risk of chd (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zocor is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zocor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - simvastatin, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; hypromellose; citric acid monohydrate; hyprolose; purified talc; iron oxide red; lactose monohydrate; microcrystalline cellulose; ascorbic acid; iron oxide yellow; butylated hydroxyanisole; titanium dioxide; carnauba wax; pregelatinised maize starch - zocor is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zocor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zocor is indicated in patients at high risk of chd (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zocor is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zocor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - simvastatin, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; butylated hydroxyanisole; pregelatinised maize starch; ascorbic acid; hypromellose; citric acid monohydrate; iron oxide red; titanium dioxide; purified talc; carnauba wax; lactose monohydrate; iron oxide yellow - zocor is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zocor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zocor is indicated in patients at high risk of chd (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zocor is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zocor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - simvastatin, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; purified talc; hypromellose; hyprolose; ascorbic acid; lactose monohydrate; microcrystalline cellulose; titanium dioxide; iron oxide red; citric acid monohydrate; pregelatinised maize starch; butylated hydroxyanisole - zocor is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zocor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zocor is indicated in patients at high risk of chd (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zocor is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zocor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

USA - engelsk - NLM (National Library of Medicine)

organon llc - simvastatin (unii: agg2fn16ev) (simvastatin - unii:agg2fn16ev) - zocor® is indicated: - to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. - as an adjunct to diet to reduce low-density lipoprotein cholesterol (ldl-c): in adults with primary hyperlipidemia. in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (hefh). - in adults with primary hyperlipidemia. - in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (hefh). - as an adjunct to other ldl-c-lowering therapies to reduce ldl-c in adults with homozygous familial hypercholesterolemia (hofh). - as an adjunct to diet for the treatment of adults with: primary dysbetalipoprote

Serbia - serbisk - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

organon d.o.o. - симвастатин - film tableta - 10mg

Serbia - serbisk - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

organon d.o.o. - симвастатин - film tableta - 20mg

Serbia - serbisk - Агенција за лекове и медицинска средства Србије (Agencija za lekove i medicins)

organon d.o.o. - симвастатин - film tableta - 40mg

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

organon france - simvastatine 40 mg - comprimé - 40 mg - pour un comprimé > simvastatine 40 mg - inhibiteur de l'hmg-coa réductase - classe pharmacothérapeutique : inhibiteur de l'hmg-coa réductase - code atc : c10aa01la substance active contenue dans zocor est la simvastatine. zocor est un médicament utilisé pour diminuer les taux du cholestérol total, de « mauvais » cholestérol (ldl-cholestérol), et les substances grasses appelées triglycérides dans le sang. de plus, zocor augmente le taux de « bon » cholestérol (hdl-cholestérol). zocor fait partie de la classe de médicaments appelés statines.le cholestérol est une des nombreuses substances grasses trouvées dans le système sanguin. votre cholestérol total est composé principalement de ldl-cholestérol et de hdl-cholestérol.le ldl cholestérol est souvent appelé le « mauvais » cholestérol parce qu'il peut s’agglomérer sur les parois de vos artères en formant une plaque. finalement, la création de cette plaque peut mener à un rétrécissement des artères. ce rétrécissement peut ralentir ou bloquer le flux sanguin vers les organes vitaux comme le cœur et le cerveau. ce blocage du flux sanguin peut entrainer une crise cardiaque ou une attaque cérébrale.le hdl cholestérol est souvent appelé le « bon » cholestérol parce qu'il aide à empêcher le mauvais cholestérol de s’agglomérer dans les artères et protège contre les maladies cardiaques.les triglycérides sont une autre forme de graisse dans votre sang qui peuvent augmenter votre risque de maladie cardiaque.vous devez continuer votre régime faisant baisser le cholestérol en prenant ce médicament.zocor est utilisé en complément d'un régime hypocholestérolémiant, si vous avez : un taux élevé de cholestérol dans votre sang (hypercholestérolémie primaire) ou des niveaux élevés de graisse dans votre sang (dyslipidémie mixte), une maladie héréditaire (hypercholestérolémie familiale homozygote) qui augmente le taux de cholestérol dans le sang. vous pouvez également recevoir d'autres traitements, une insuffisance coronarienne ou un risque élevé d'insuffisance coronarienne (parce que vous avez un diabète, avez un antécédent d'accident vasculaire cérébral ou une maladie vasculaire d'origine athéroscléreuse). zocor peut prolonger votre vie en réduisant le risque de problèmes cardiaques, indépendamment de la quantité de votre cholestérol sanguin.chez la plupart des gens, il n'y a pas de symptôme immédiat dû à un taux élevé de cholestérol. votre médecin peut mesurer votre cholestérol à l'aide d'un simple test sanguin. consultez votre médecin régulièrement, vérifiez votre cholestérol, et discutez avec votre médecin des résultats à atteindre.